Congenital Hyperinsulinism (CHI)

Zealand Pharma Reports First Patient Treated in Phase 3 Trial for Treatment of Congenital Hyperinsulinism

Mar 8, 2019 | Congenital Hyperinsulinism (CHI), Pediatrics

Zealand Pharma reports via Globe News Wire that it dosed its first patient in its Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism (CHI). CHI is a rare pediatric disease with high unmet medical need according to the industry sponsor....

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Zealand Pharma Reports First Patient Treated in Phase 3 Trial for Treatment of Congenital Hyperinsulinism

Pin It on Pinterest